Gilead Sciences (GILD) Acquires Tubulis for $3.15B to Expand Oncology Portfolio

Gilead Sciences Inc. (NASDAQ:GILD) is one of the cheap NASDAQ stocks to buy right now. On May 21, Gilead Sciences completed the acquisition of Tubulis GmbH, a Germany-based biotechnology company, for $3.15 billion in upfront payments plus up to $1.85 billion in potential milestone considerations. This strategic move bolsters Gilead’s oncology portfolio by integrating Tubulis’ proprietary antibody-drug conjugate/ADC platform and promising clinical assets, including the lead candidate TUB-040, which is currently being evaluated for platinum-resistant ovarian and non-small cell lung cancers.

As part of the acquisition, the Tubulis team will remain in Munich to establish “The Tubulis ADC Innovation Center.” This new hub will serve as the company’s center for ongoing ADC research, manufacturing, and clinical development, allowing Gilead to use Tubulis’ expertise in creating highly selective, next-generation therapies designed to maximize anti-tumor activity while limiting side effects.

Gilead Sciences (GILD) Acquires Tubulis for $3.15B to Expand Oncology Portfolio

The acquisition deepens Gilead Sciences Inc.’s (NASDAQ:GILD) commitment to advancing transformative cancer treatments through targeted technologies. By combining Gilead’s existing oncology infrastructure with Tubulis’ innovative ADC platform, the company aims to address significant gaps in care for patients with challenging forms of solid tumors, further cementing its position as a leader in oncology innovation.

Gilead Sciences Inc. (NASDAQ:GILD) is a drug manufacturer that develops medicines for unmet medical needs. The company provides treatments for HIV-1, chronic hepatitis C, primary biliary cholangitis, chronic hepatitis B, and serious invasive fungal infections. It also offers T-cell and CAR T-cell therapies for adult patients, intravenous injections, and treatments for COVID-19.

While we acknowledge the risk and potential of GILD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GILD and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1